Amplia Therapeutics Ltd. (INNMF)

[Smilin_B]

ELEASE 26 April 2018
Results of General Meeting
Innate Immunotherapeutics Limited (ASX Code: IIL) is pleased to confirm that each of the resolutions
considered at its General Meeting held earlier today were passed.
Results of the General Meeting are summarised as follows:
# RESOLUTION PASSED/
FAILED
VOTE
SoH*/
POLL
PROXIES
FOR
PROXIES
AGAINST
PROXIES
DISCRETION
PROXIES
ABSTAIN
1 Consolidation of Capital Passed SoH 57,087,386 1,048,247 1,344,637 1,210,868
2 Acquisition of Amplia Passed SoH 59,178,282 25,512 1,344,637 142,707
3 Issue of Consideration
Shares to Amplia Passed SoH 59,112,491 60,892 1,344,637 173,118
4 Appointment of Andrew
Cooke as a Director Passed SoH 58,858,276 61,431 1,398,504 372,927
5 Appointment of Christian
Behrenbruch as a Director Passed SoH 58,376,787 675,512 1,398,504 240,335
6 Appointment of Warwick
Tong as a Director Passed SoH 58,432,754 691,929 1,342,537 223,918
7 Appointment of Christopher
Burns as a Director Passed SoH 58,367,754 675,512 1,407,537 240,335
*Show of Hands
For Further Information:
Mr Simon Wilkinson, CEO
[phone]
or visit the Innate Immunotherapeutics website at www.innateimmuno.com